Paper Details

  1. Home
  2. Paper Details

6-month versus 36-month isoniazid preventive treatment for tuberculosis in adults with HIV infection in Botswana: a randomised, double-blind, placebo-controlled trial.

Author: AgizewTefera B, BozemanLorna, CastroKenneth G, DavisMargarett K, KilmarxPeter H, MoetiThemba L, MoffatHoward J, MosimaneotsileBarudi, MotsamaiOaitse I, NyirendaSamba, SamandariTaraz, ShangNong, SibandaThabisa, TalbotElizabeth A, TedlaZegabriel, WellsCharles D

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, U.S. Gov't, Non-P.H.S.Research funding provided by US government agencies other than the Public Health Service.
Research Support, U.S. Gov't, P.H.S.Research funding provided by the Public Health Service (PHS).

Overview

36 months' isoniazid prophylaxis was more effective for prevention of tuberculosis than was 6-month prophylaxis in individuals with HIV infection, and chiefly benefited those who were tuberculin skin test positive. We recorded 34 (3·4%) cases of incident tuberculosis in 989 participants allocated to the control group and 20 (2·0%) in 1006 allocated to the continued isoniazid group (incidence 1·26% per year vs 0·72%; hazard ratio 0·57, 95% CI 0·33-0·99, p=0·047).
Paper Details　
Original Abstract of the Article :
BACKGROUND: In accordance with WHO guidelines, people with HIV infection in Botswana receive daily isoniazid preventive therapy against tuberculosis without obtaining a tuberculin skin test, but duration of prophylaxis is restricted to 6 months. We aimed to assess effectiveness of extended isoniazid...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/S0140-6736(11)60204-3

データ提供：米国国立医学図書館（NLM）

Prolonging Protection: The Case for Extended Isoniazid Prophylaxis in HIV-Positive Individuals

Tuberculosis (TB), like a lurking predator in the desert, can pose a serious threat, especially for those living with HIV. This study, like a vigilant sentinel guarding against the dangers of the desert, investigates the effectiveness of extended isoniazid prophylaxis, a preventive medication, for those with HIV infection. Researchers are comparing the impact of 6 months versus 36 months of isoniazid prophylaxis on TB incidence. This study is like a well-trained caravan leader, seeking a safe and effective route through the desert of TB. The researchers found that extended isoniazid prophylaxis significantly reduced the risk of TB in HIV-positive individuals, offering a longer-lasting shield of protection. This is like discovering a hidden oasis of protection in the desert, offering a safe haven from the dangers of TB.

The Power of Extended Protection

This study highlights the importance of extended isoniazid prophylaxis in reducing the risk of TB in HIV-positive individuals. The researchers' findings suggest that this preventive measure can significantly improve health outcomes and reduce the burden of TB in this vulnerable population. This is like finding a new weapon in the fight against TB, offering a stronger defense against this formidable foe.

Navigating the Desert of TB

This research reminds us that TB can be a serious threat, especially for those with weakened immune systems. Just as a camel needs to find the right path to avoid dangerous areas in the desert, patients with HIV need to take steps to protect themselves from TB. This could involve receiving regular medical checkups, following prescribed medications, and taking preventive measures like extended isoniazid prophylaxis.

Dr.Camel's Conclusion

This study underscores the importance of preventive care and the power of extended prophylaxis in mitigating the risk of TB in HIV-positive individuals. Like a camel who has learned to navigate the treacherous desert with wisdom and foresight, we must be diligent in taking steps to protect those who are vulnerable to TB. This research offers a valuable tool for preventing this debilitating disease, paving the way towards a healthier future for those living with HIV.

Date :
  1. Date Completed 2011-07-06
  2. Date Revised 2022-04-08
Further Info :

Pubmed ID

21492926

DOI: Digital Object Identifier

10.1016/S0140-6736(11)60204-3

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.